AbbVie

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
AbbVie
TickerABBV
CIK #0001551152
CUSIP00287Y109
SectorLife Sciences
IndustryPharmaceutical Preparations
Phone84793279
Address1 North Waukegan Road
North Chicago, IL 60064
Source [EDGAR]
Market Cap, 13F ($BB)
190152114763802011201320152018
Business

AbbVie(1) is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.

In June 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan). Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including aesthetics, eye care, neuroscience, gastroenterology and women's health. See Note 5 to the Consolidated Financial Statements for additional information regarding the proposed acquisition.

AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

CIK Filing 2011 - 2021
[0001551152] 10-K
[0001551152] 10-Q
[0001551152] 3
[0001551152] 4
[0001551152] 8-K
[0001551152] D
[0001551152] SC 13D
[0001551152] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Abbvie Inc Exicure Inc [2017-10-06] 5.5
Capital Research Global Investors Abbvie Inc [2016-11-10] 10.0
Abbvie Inc Reata Pharmaceuticals Inc [2016-06-06] 17.93
Capital Research Global Investors Abbvie Inc [2014-02-13] 6.3
Vanguard Group Inc Abbvie Inc [2014-02-10] 5.17
Abbvie Inc Enanta Pharmaceuticals Inc [2014-02-07] 5.97
BlackRock Inc Abbvie Inc [2014-01-28] 6.6
Form 3/4/5 Filer 2011-2021
Stewart Jeffrey Ryan
Gonzalez Richard A
Schumacher Laura J
Richmond Timothy J
Gosebruch Henry O
SORG Elaine K
Alban Carlos
Saleki-Gerhardt Azita
Severino Michael
Liddy Edward M
RAPP Edward J
Alpern Robert J
Freyman Thomas C
Strom Carrie C
Durkin Brian L
Waddell Frederick H
Tilton Glenn F
Roberts Rebecca B
Meyer Melody B
Hart Brett J
Burnside William HL
Austin Roxanne S
Michael Robert A
Hudson Thomas J
Donoghoe Nicholas
Chase William J
Reata Pharmaceuticals Inc
Hurwich Thomas A
Roberts Roy S
Leonard John M
Abbott Laboratories
Linder Greg W
MM Shares Owned of 1,504.2 MM Total
Firm Period DFND Voting Shares
Vanguard Group Inc [2020-09-30] SOLE 0.0 136.1
BlackRock Inc. [2020-09-30] SOLE 104.3 122.0
State Street Corp [2020-09-30] DFND 67.7 78.2
Capital Research Global Investors [2020-09-30] DFND 40.8 40.8
Price T Rowe Associates Inc /MD/ [2020-09-30] SOLE 13.7 32.7
FMR LLC [2020-09-30] DFND 2.8 30.3
JPMorgan Chase & Co [2020-09-30] DFND 25.9 28.7
Geode Capital Management LLC [2020-09-30] DFND 26.1 26.1
Northern Trust Corp [2020-09-30] DFND 7.9 22.2
Berkshire Hathaway Inc [2020-09-30] DFND 21.3 21.3
Nuveen Asset Management LLC [2020-09-30] DFND 20.0 20.1
Bank of New York Mellon Corp [2020-09-30] DFND 16.9 20.1
Bank of America Corp /DE/ [2020-09-30] DFND 5.9 18.5
Henderson Group PLC [2020-09-30] DFND 0.0 17.0
Morgan Stanley [2020-09-30] DFND 0.9 13.7
Renaissance Technologies LLC [2020-09-30] SOLE 13.3 13.5
Deutsche Bank AG [2020-09-30] DFND 6.4 11.9
Susquehanna International Group LLP [2020-09-30] DFND 2.4 11.0
Royal Bank of Canada [2020-09-30] DFND 10.4 11.0
Legal & General Group Plc [2020-09-30] DFND 7.8 10.8
Goldman Sachs Group Inc [2020-09-30] DFND 9.3 10.7
Wells Fargo & Co/Mn [2020-09-30] DFND 8.6 10.4
UBS Group AG [2020-09-30] DFND 0.0 10.1
Capital Research & Management Co - Division 3 [2020-09-30] DFND 10.0 10.0
Orbis Allan Gray Ltd [2020-09-30] DFND 9.3 9.3
Sumitomo Mitsui Trust Holdings, Inc. [2020-09-30] DFND 8.4 8.4
Vanguard Group Inc [2020-09-30] DFND 0.0 8.3
Schwab Charles Investment Management Inc [2020-09-30] SOLE 8.1 8.1
Ameriprise Financial Inc [2020-09-30] DFND 0.0 8.0
State Farm Mutual Automobile Insurance Co [2020-09-30] SOLE 7.5 7.5
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com